Glaukos Stock Price, News & Analysis (NYSE:GKOS)

$28.47 0.14 (0.49 %)
(As of 01/17/2018 06:05 AM ET)
Previous Close$28.33
Today's Range$28.15 - $29.61
52-Week Range$23.08 - $52.49
Volume555,700 shs
Average Volume471,490 shs
Market Capitalization$979.24 million
P/E Ratio-711.57
Dividend YieldN/A
Beta1.02

About Glaukos (NYSE:GKOS)

Glaukos logoGlaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.

Receive GKOS News and Ratings via Email

Sign-up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Devices & Implants
Sub-IndustryN/A
SectorMedical
SymbolNYSE:GKOS
CUSIPN/A
Phone949-367-9600

Debt

Debt-to-Equity RatioN/A
Current Ratio6.93%
Quick Ratio6.48%

Price-To-Earnings

Trailing P/E Ratio-711.572106973257
Forward P/E Ratio-949.00
P/E Growth41.06

Sales & Book Value

Annual Sales$114.40 million
Price / Sales8.60
Cash Flow$0.28 per share
Price / Cash100.56
Book Value$3.50 per share
Price / Book8.13

Profitability

Trailing EPS($0.04)
Net Income$4.52 million
Net Margins-0.64%
Return on Equity3.50%
Return on Assets3.05%

Miscellaneous

Employees264
Outstanding Shares34,560,000

Glaukos (NYSE:GKOS) Frequently Asked Questions

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

How were Glaukos' earnings last quarter?

Glaukos Corp (NYSE:GKOS) released its quarterly earnings data on Tuesday, November, 7th. The medical instruments supplier reported $0.04 EPS for the quarter, beating analysts' consensus estimates of ($0.02) by $0.06. The medical instruments supplier earned $40.41 million during the quarter, compared to analyst estimates of $38.69 million. Glaukos had a negative net margin of 0.64% and a positive return on equity of 3.50%. Glaukos's revenue was up 36.6% compared to the same quarter last year. During the same period last year, the business earned $0.03 earnings per share. View Glaukos' Earnings History.

When will Glaukos make its next earnings announcement?

Glaukos is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Glaukos.

Where is Glaukos' stock going? Where will Glaukos' stock price be in 2018?

6 analysts have issued 1-year price targets for Glaukos' shares. Their predictions range from $38.00 to $55.00. On average, they expect Glaukos' share price to reach $45.50 in the next year. View Analyst Ratings for Glaukos.

What are Wall Street analysts saying about Glaukos stock?

Here are some recent quotes from research analysts about Glaukos stock:

  • 1. According to Zacks Investment Research, "Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. " (11/13/2017)
  • 2. Cantor Fitzgerald analysts commented, "Executing Well in a Slightly Adverse Environment. Glaukos reported 37% YoY revenue growth, falling a little short of the 40%+ growth since the launch of iStent slightly more than four years ago (88% of the sales were recorded in the U.S.). The company reported to be on track to have trained >3,000 surgeons by YE17. Glaukos operated in an environment, which was affected by a number of factors: 1: the slow institution of higher reimbursement (challenging during implementation, but favorable afterwards) by commercial payors (20% of total); 2: hurricane-caused delays in surgery ($1 million impact in 3Q17); 3: a negative impact by a single Medicare operator (lowering surgeon’s fees) and by continued sampling and perhaps early sales by competitor Alcon (wholly owned by NVS [Not Covered]). Long term, we believe Glaukos’ iStent has demonstrated significant long-term benefit and cost efficiency to maintain a commercial and competitive advantage. The company remained cautious about 2018, due to the expanded launch by Alcon, a second competitor potentially arriving to the market by 2H18 (Hydrus by Ivantis [private]) and the relatively modest contribution by iStent Inject (PMA to be submitted by YE17). 2018 guidance will be introduced in January at the 4Q17 earnings call." (11/7/2017)

Who are some of Glaukos' key competitors?

Who are Glaukos' key executives?

Glaukos' management team includes the folowing people:

  • William J. Link Ph.D., Independent Chairman of the Board (Age 71)
  • Thomas William Burns, President, Chief Executive Officer and Director (Age 56)
  • Joseph E. Gilliam, Chief Financial Officer, Senior Vice President - Corporate Development (Age 41)
  • Chris M. Calcaterra, Chief Commercial Officer and Chief Operating Officer (Age 56)
  • L. Jay Katz, Chief Medical Officer
  • Mark J. Foley, Independent Director (Age 51)
  • David F. Hoffmeister, Independent Director (Age 62)
  • Gilbert H. Kliman M.D., Independent Director (Age 58)
  • Jonathan Todd Silverstein J.D., Independent Director (Age 50)
  • Marc A. Stapley, Independent Director (Age 46)

When did Glaukos IPO?

(GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Who owns Glaukos stock?

Glaukos' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Wasatch Advisors Inc. (0.07%) and Bank of Montreal Can (0.02%). Company insiders that own Glaukos stock include Aimee S Weisner, Chris M Calcaterra, Jonathan Silverstein, Joseph E Gilliam, Montreux Equity Partners Iv Lp, Orbimed Advisors Llc, Richard L Harrison, Thomas William Burns and William J Phd Link. View Institutional Ownership Trends for Glaukos.

Who sold Glaukos stock? Who is selling Glaukos stock?

Glaukos' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold Glaukos company stock in the last year include Orbimed Advisors Llc and Thomas William Burns. View Insider Buying and Selling for Glaukos.

Who bought Glaukos stock? Who is buying Glaukos stock?

Glaukos' stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc.. Company insiders that have bought Glaukos stock in the last two years include Aimee S Weisner and Joseph E Gilliam. View Insider Buying and Selling for Glaukos.

How do I buy Glaukos stock?

Shares of Glaukos can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Glaukos' stock price today?

One share of Glaukos stock can currently be purchased for approximately $28.47.

How big of a company is Glaukos?

Glaukos has a market capitalization of $979.24 million and generates $114.40 million in revenue each year. The medical instruments supplier earns $4.52 million in net income (profit) each year or ($0.04) on an earnings per share basis. Glaukos employs 264 workers across the globe.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]


MarketBeat Community Rating for Glaukos (GKOS)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  210 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  320
MarketBeat's community ratings are surveys of what our community members think about Glaukos and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Glaukos (NYSE:GKOS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $45.50$47.50$49.83$49.20
Price Target Upside: 61.35% upside91.15% upside52.86% upside18.01% upside

Glaukos (NYSE:GKOS) Consensus Price Target History

Price Target History for Glaukos (NYSE:GKOS)

Glaukos (NYSE:GKOS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/10/2018Cantor FitzgeraldSet Price TargetBuy$48.00MediumView Rating Details
12/11/2017BMO Capital MarketsReiterated RatingBuyLowView Rating Details
11/13/2017StephensReiterated RatingOverweight$47.00 -> $40.00N/AView Rating Details
9/15/2017Piper Jaffray CompaniesReiterated RatingPositive -> Buy$38.00HighView Rating Details
9/14/2017Stifel NicolausReiterated RatingBuyHighView Rating Details
8/3/2017Roth CapitalLower Price TargetBuy$60.00 -> $54.00HighView Rating Details
10/27/2016Wells Fargo & CoInitiated CoverageOutperformN/AView Rating Details
3/2/2016JPMorgan Chase & Co.Lower Price TargetOverweight$32.00 -> $28.00N/AView Rating Details
(Data available from 1/17/2016 forward)

Earnings

Glaukos (NYSE:GKOS) Earnings History and Estimates Chart

Earnings by Quarter for Glaukos (NYSE:GKOS)

Glaukos (NYSE GKOS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018        
11/7/2017Q3 2017($0.02)$0.04$38.69 million$40.41 millionViewN/AView Earnings Details
8/2/2017Q2 2017$0.06$0.06ViewN/AView Earnings Details
5/3/2017Q1 2017($0.02)$0.02ViewN/AView Earnings Details
3/1/2017Q416$0.00$0.00$29.49 million$33.17 millionViewListenView Earnings Details
11/10/2016Q316($0.01)$0.03$27.21 million$29.60 millionViewN/AView Earnings Details
8/1/2016Q216($0.04)$0.06$24.45 million$28.60 millionViewN/AView Earnings Details
5/3/2016Q116($0.15)$0.03$18.77 million$23.10 millionViewN/AView Earnings Details
3/1/2016Q415($0.13)($0.07)$20.07 million$20.28 millionViewN/AView Earnings Details
11/10/2015Q315($0.17)($0.07)$17.93 million$19.00 millionViewListenView Earnings Details
8/12/2015Q2 2015($1.14)($1.30)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Glaukos (NYSE:GKOS) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.03 EPS
Next Year EPS Consensus Estimate: $0.03 EPS

Dividends

Dividend History for Glaukos (NYSE:GKOS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Glaukos (NYSE GKOS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.40%
Institutional Ownership Percentage: 99.23%
Insider Trades by Quarter for Glaukos (NYSE:GKOS)
Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Glaukos (NYSE GKOS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/22/2017Joseph E GilliamCFOBuy2,100$23.84$50,064.00102,100View SEC Filing  
9/7/2017Thomas William BurnsCEOSell73,788$41.36$3,051,871.68View SEC Filing  
9/5/2017Orbimed Advisors LlcDirectorSell580,200$38.73$22,471,146.00View SEC Filing  
9/5/2017Thomas William BurnsCEOSell1,212$41.25$49,995.00View SEC Filing  
8/17/2017Orbimed Advisors LlcDirectorSell325,000$37.93$12,327,250.00View SEC Filing  
3/14/2017Orbimed Advisors LlcDirectorSell382,538$45.33$17,340,447.54View SEC Filing  
2/2/2017Thomas William BurnsCEOSell50,000$42.58$2,129,000.00View SEC Filing  
1/13/2017Chris M CalcaterraInsiderSell18,136$40.01$725,621.36254,413View SEC Filing  
1/13/2017Richard L HarrisonCFOSell20,634$40.00$825,360.0015,709View SEC Filing  
1/9/2017Chris M CalcaterraInsiderSell20,000$38.02$760,400.00260,000View SEC Filing  
1/9/2017Thomas William BurnsCEOSell40,000$37.60$1,504,000.00View SEC Filing  
1/6/2017Richard L HarrisonCFOSell20,634$35.58$734,157.722,656View SEC Filing  
11/17/2016William J Phd LinkDirectorSell30,000$33.78$1,013,400.00View SEC Filing  
11/15/2016Thomas William BurnsCEOSell200,120$33.68$6,740,041.601,388View SEC Filing  
10/24/2016Chris M CalcaterraInsiderSell20,000$36.01$720,200.00260,000View SEC Filing  
10/20/2016Chris M CalcaterraInsiderSell40,000$34.76$1,390,400.00280,000View SEC Filing  
8/12/2016Jonathan SilversteinDirectorSell292,938$33.69$9,869,081.22View SEC Filing  
8/3/2016Orbimed Advisors LlcDirectorSell425,000$30.59$13,000,750.00View SEC Filing  
7/27/2016Richard L HarrisonCFOSell10,000$35.01$350,100.0011,388View SEC Filing  
7/13/2016Thomas William BurnsCEOSell162,254$30.07$4,878,977.781,388View SEC Filing  
7/12/2016Richard L HarrisonCFOSell5,700$30.00$171,000.007,088View SEC Filing  
6/20/2016Richard L HarrisonCFOSell4,300$30.00$129,000.005,688View SEC Filing  
6/20/2016Thomas William BurnsCEOSell7,997$30.00$239,910.001,388View SEC Filing  
6/15/2016Chris M CalcaterraInsiderSell45,464$28.46$1,293,905.44273,600View SEC Filing  
6/6/2016Thomas William BurnsCEOSell24,578$25.16$618,382.481,388View SEC Filing  
6/3/2016Thomas William BurnsCEOSell422$25.00$10,550.001,388View SEC Filing  
6/1/2016Thomas William BurnsCEOSell25,000$23.90$597,500.001,388View SEC Filing  
5/25/2016Thomas William BurnsCEOSell300$25.00$7,500.001,388View SEC Filing  
5/4/2016Chris M CalcaterraInsiderSell74,536$24.40$1,818,678.40245,836View SEC Filing  
5/4/2016Richard L HarrisonCFOSell30,000$24.59$737,700.003,556View SEC Filing  
5/4/2016Thomas William BurnsCEOSell36,700$24.67$905,389.001,388View SEC Filing  
3/4/2016Aimee S WeisnerDirectorBuy2,500$16.03$40,075.00View SEC Filing  
2/25/2016Montreux Equity Partners Iv LpMajor ShareholderSell70,000$16.16$1,131,200.00View SEC Filing  
12/31/2015Richard L HarrisonCFOBuy1,388$15.30$21,236.404,656View SEC Filing  
11/12/2015Aimee S WeisnerDirectorBuy2,500$21.83$54,575.002,500View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Glaukos (NYSE GKOS) News Headlines

Source:
DateHeadline
Glaukos Corporation (GKOS) Announces iDose Travoprost Achieved Sustained IOP Reduction, Favorable Safety Profile in 12-Month Interim CohortGlaukos Corporation (GKOS) Announces iDose Travoprost Achieved Sustained IOP Reduction, Favorable Safety Profile in 12-Month Interim Cohort
www.streetinsider.com - January 10 at 10:05 AM
Glaukos Corporation (GKOS) Reports Submission of IDE Application ... - StreetInsider.comGlaukos Corporation (GKOS) Reports Submission of IDE Application ... - StreetInsider.com
www.streetinsider.com - January 4 at 4:54 PM
Glaukos Corporation (GKOS) Reports Submission of IDE Application to FDA to Study iStent infinite Trabecular Micro-Bypass SystemGlaukos Corporation (GKOS) Reports Submission of IDE Application to FDA to Study iStent infinite Trabecular Micro-Bypass System
www.streetinsider.com - January 3 at 4:56 PM
Glaukos Submits IDE Application to FDA to Study iStent infinite™ Trabecular Micro-Bypass SystemGlaukos Submits IDE Application to FDA to Study iStent infinite™ Trabecular Micro-Bypass System
finance.yahoo.com - January 3 at 9:19 AM
Glaukos Corporation (GKOS) Receives Consensus Recommendation of "Buy" from BrokeragesGlaukos Corporation (GKOS) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 1 at 4:10 PM
Glaukos Corporation (GKOS) Expected to Post Quarterly Sales of $40.81 MillionGlaukos Corporation (GKOS) Expected to Post Quarterly Sales of $40.81 Million
www.americanbankingnews.com - December 31 at 9:54 AM
Glaukos Corporation (GKOS) Reports Submission of Pre-Market Approval Application for the iStent Inject Trabecular Micro-BypassGlaukos Corporation (GKOS) Reports Submission of Pre-Market Approval Application for the iStent Inject Trabecular Micro-Bypass
www.streetinsider.com - December 27 at 5:25 PM
ETFs with exposure to Glaukos Corp. : December 26, 2017ETFs with exposure to Glaukos Corp. : December 26, 2017
finance.yahoo.com - December 27 at 5:25 PM
Glaukos Has 84% Upside Potential In 2018, According To CantorGlaukos Has 84% Upside Potential In 2018, According To Cantor
finance.yahoo.com - December 27 at 5:25 PM
Glaukos Announces Participation in J.P. Morgan Healthcare ConferenceGlaukos Announces Participation in J.P. Morgan Healthcare Conference
finance.yahoo.com - December 27 at 5:25 PM
Contrasting Glaukos (GKOS) & Orthopediatrics (KIDS)Contrasting Glaukos (GKOS) & Orthopediatrics (KIDS)
www.americanbankingnews.com - December 27 at 10:00 AM
Glaukos (GKOS) Given a $48.00 Price Target by Cantor Fitzgerald AnalystsGlaukos (GKOS) Given a $48.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - December 27 at 9:53 AM
Glaukos Corp. :GKOS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017Glaukos Corp. :GKOS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017
finance.yahoo.com - December 22 at 10:07 AM
$40.81 Million in Sales Expected for Glaukos Corporation (GKOS) This Quarter$40.81 Million in Sales Expected for Glaukos Corporation (GKOS) This Quarter
www.americanbankingnews.com - December 14 at 6:02 PM
Glaukos (GKOS) Buy Rating Reiterated at BMO Capital MarketsGlaukos' (GKOS) Buy Rating Reiterated at BMO Capital Markets
www.americanbankingnews.com - December 12 at 1:42 PM
Why SCANA, Glaukos, and Juno Therapeutics Slumped TodayWhy SCANA, Glaukos, and Juno Therapeutics Slumped Today
finance.yahoo.com - December 11 at 5:03 PM
Glaukos (GKOS) & The Competition Head-To-Head ComparisonGlaukos (GKOS) & The Competition Head-To-Head Comparison
www.americanbankingnews.com - December 6 at 7:25 PM
Critical Survey: Glaukos (GKOS) versus Its RivalsCritical Survey: Glaukos (GKOS) versus Its Rivals
www.americanbankingnews.com - December 4 at 1:28 PM
Head to Head Analysis: Glaukos (GKOS) & Its RivalsHead to Head Analysis: Glaukos (GKOS) & Its Rivals
www.americanbankingnews.com - December 4 at 3:26 AM
Head to Head Survey: Glaukos (GKOS) & Its CompetitorsHead to Head Survey: Glaukos (GKOS) & Its Competitors
www.americanbankingnews.com - December 1 at 5:39 AM
Glaukos (GKOS) & Its Rivals Head-To-Head SurveyGlaukos (GKOS) & Its Rivals Head-To-Head Survey
www.americanbankingnews.com - November 29 at 11:32 PM
Head-To-Head Contrast: Glaukos (GKOS) vs. Its RivalsHead-To-Head Contrast: Glaukos (GKOS) vs. Its Rivals
www.americanbankingnews.com - November 28 at 9:08 PM
Glaukos Corporation (GKOS) CFO Joseph E. Gilliam Buys 2,100 SharesGlaukos Corporation (GKOS) CFO Joseph E. Gilliam Buys 2,100 Shares
www.americanbankingnews.com - November 27 at 1:39 PM
Head to Head Survey: Glaukos (GKOS) and Its PeersHead to Head Survey: Glaukos (GKOS) and Its Peers
www.americanbankingnews.com - November 27 at 10:58 AM
Glaukos Corporation (GKOS) Expected to Announce Quarterly Sales of $40.81 MillionGlaukos Corporation (GKOS) Expected to Announce Quarterly Sales of $40.81 Million
www.americanbankingnews.com - November 26 at 12:10 PM
Glaukos (GKOS) versus Its Competitors Head to Head AnalysisGlaukos (GKOS) versus Its Competitors Head to Head Analysis
www.americanbankingnews.com - November 25 at 3:20 PM
Head-To-Head Contrast: Glaukos Corporation (GKOS) vs. The CompetitionHead-To-Head Contrast: Glaukos Corporation (GKOS) vs. The Competition
www.americanbankingnews.com - November 25 at 9:26 AM
Critical Review: Glaukos Corporation (GKOS) versus Its PeersCritical Review: Glaukos Corporation (GKOS) versus Its Peers
www.americanbankingnews.com - November 25 at 3:26 AM
Glaukos Is Now Oversold (GKOS)Glaukos Is Now Oversold (GKOS)
www.thestreet.com - November 21 at 7:06 PM
Glaukos Corporation (GKOS) versus Its Peers Head to Head ComparisonGlaukos Corporation (GKOS) versus Its Peers Head to Head Comparison
www.americanbankingnews.com - November 20 at 7:32 PM
Glaukos Corporation (GKOS) and Its Peers Head to Head SurveyGlaukos Corporation (GKOS) and Its Peers Head to Head Survey
www.americanbankingnews.com - November 20 at 5:24 PM
Reviewing Glaukos Corporation (GKOS) and Its PeersReviewing Glaukos Corporation (GKOS) and Its Peers
www.americanbankingnews.com - November 17 at 1:40 PM
BMO Capital Markets Cuts Glaukos Corporation (GKOS) Price Target to $38.00BMO Capital Markets Cuts Glaukos Corporation (GKOS) Price Target to $38.00
www.americanbankingnews.com - November 16 at 6:50 PM
ETFs with exposure to Glaukos Corp. : November 16, 2017ETFs with exposure to Glaukos Corp. : November 16, 2017
finance.yahoo.com - November 16 at 2:45 PM
Glaukos Corporation (GKOS) Raised to Hold at Zacks Investment ResearchGlaukos Corporation (GKOS) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - November 13 at 11:46 PM
Glaukos Corporations (GKOS) Overweight Rating Reaffirmed at StephensGlaukos Corporation's (GKOS) Overweight Rating Reaffirmed at Stephens
www.americanbankingnews.com - November 13 at 8:48 AM
Glaukos Corporation (GKOS) Receives Average Recommendation of "Buy" from BrokeragesGlaukos Corporation (GKOS) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 12 at 4:22 PM
Glaukos (GKOS) CEO Thomas Burns on Q3 2017 Results - Earnings Call TranscriptGlaukos' (GKOS) CEO Thomas Burns on Q3 2017 Results - Earnings Call Transcript
www.msn.com - November 9 at 6:05 AM
Glaukos Corp to Host Earnings CallGlaukos Corp to Host Earnings Call
finance.yahoo.com - November 9 at 6:05 AM
Glaukos Corporation (GKOS) Tops Q3 EPS by 5c - StreetInsider.comGlaukos Corporation (GKOS) Tops Q3 EPS by 5c - StreetInsider.com
www.streetinsider.com - November 8 at 8:03 AM
Glaukos (GKOS) CEO Thomas Burns on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaGlaukos' (GKOS) CEO Thomas Burns on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 8 at 8:03 AM
Glaukos Corporation Announces Third Quarter 2017 Financial ResultsGlaukos Corporation Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 8:03 AM
Glaukos beats Street 3Q forecastsGlaukos beats Street 3Q forecasts
finance.yahoo.com - November 8 at 8:03 AM
Edited Transcript of GKOS earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of GKOS earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 8 at 8:03 AM
Glaukos Corporation (GKOS) Stock Rating Reaffirmed by Cantor FitzgeraldGlaukos Corporation (GKOS) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - November 7 at 11:51 PM
Glaukos Corporation (GKOS) Posts  Earnings Results, Beats Estimates By $0.05 EPSGlaukos Corporation (GKOS) Posts Earnings Results, Beats Estimates By $0.05 EPS
www.americanbankingnews.com - November 7 at 11:50 PM
Glaukos Corporation (GKOS) and Its Peers Critical ComparisonGlaukos Corporation (GKOS) and Its Peers Critical Comparison
www.americanbankingnews.com - November 7 at 7:22 PM
 Brokerages Expect Glaukos Corporation (GKOS) Will Post Quarterly Sales of $38.85 Million Brokerages Expect Glaukos Corporation (GKOS) Will Post Quarterly Sales of $38.85 Million
www.americanbankingnews.com - November 7 at 4:36 AM
 Brokerages Expect Glaukos Corp (GKOS) Will Post Earnings of -$0.01 Per Share Brokerages Expect Glaukos Corp (GKOS) Will Post Earnings of -$0.01 Per Share
www.americanbankingnews.com - November 5 at 9:24 AM
Glaukos Announces Participation in Stifel 2017 Healthcare ConferenceGlaukos Announces Participation in Stifel 2017 Healthcare Conference
finance.yahoo.com - October 31 at 8:12 PM

SEC Filings

Glaukos (NYSE:GKOS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Glaukos (NYSE:GKOS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Glaukos (NYSE GKOS) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.